Biohaven Pharmaceutical

-$0.40 (-0.28%) Today

$0.00 (0.00%) As of 11:19 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BHVN and other ETFs, options, and stocks.

About BHVN

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.

CEO

Vladimir Coric

Employees

928

Headquarters

New Haven, Connecticut

Founded

2013

BHVN Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

4.22M

High today

$143.17

Low today

$142.44

Open price

$142.90

Volume

1.86M

52 Week high

$151.51

52 Week low

$77.63

BHVN News

ReutersMay 23

UPDATE 1-Biohaven's drug for genetic neurological disease fails late-stage study

(Adds background on Pfizer deal, details on disease) May 23 (Reuters) - Biohaven Pharmaceutical said on Monday a late-stage trial of its drug against spinocere

Analyst ratings

Buy

90.9%

Hold

9.1%

Sell

BHVN Earnings

-$2.97

-$2.52

-$2.07

-$1.62

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Estimated

-$2.53 per share

Actual

-$1.62 per share

Replay Earnings Call

Why Robinhood?

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. View more

UPDATE 1-Biohaven's drug for genetic neurological disease fails late-stage study

91%

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders.